Meeting
2021 ASCO Annual Meeting
A randomized phase III study of immune checkpoint inhibition with chemotherapy in treatment-naive metastatic anal cancer patients: A trial of the ECOG-ACRIN cancer research group (EA2176).
Authors
Marc Thomas Roth
Vanderbilt-Ingram Cancer Center, Nashville, TN
Marc Thomas Roth , Paul J. Catalano , Kristen Keon Ciombor , Al Bowen Benson III, Xin Yao , Rona Yaeger , Mohamed E. Salem , Van K. Morris II, David H. Henry , Jennifer G. Whisenant , Peter J. O'Dwyer , Cathy Eng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Anal Cancer
Clinical Trial Registration Number
NCT04444921
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS3614)
DOI
10.1200/JCO.2021.39.15_suppl.TPS3614
Abstract #
TPS3614
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
First Author: Ana Oaknin
Poster
2012 ASCO Annual Meeting
Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal.
First Author: Cathy Eng
Poster
2023 ASCO Annual Meeting
Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R).
First Author: Patrick M. Forde
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial.
First Author: Zev A. Wainberg